AAAAAA
Results:
1-9
|
Results: 9
Authors:
Roth, BD
Sliskovic, DR
Citation: Bd. Roth et Dr. Sliskovic, Endocrine and metabolic agents - Preface, CUR PHARM D, 7(6), 2001, pp. NIL_2-NIL_2
Authors:
Roth, BD
Sliskovic, DR
Citation: Bd. Roth et Dr. Sliskovic, Endocrine and metabolic agents - Preface, CUR PHARM D, 7(4), 2001, pp. NIL_2-NIL_2
Authors:
Bocan, TMA
Krause, BR
Rosebury, WS
Lu, XK
Dagle, C
Mueller, SB
Auerbach, B
Sliskovic, DR
Citation: Tma. Bocan et al., The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression, ATHEROSCLER, 157(1), 2001, pp. 97-105
Authors:
Peterson, JT
Hallak, H
Johnson, L
Li, H
O'Brien, PM
Sliskovic, DR
Bocan, TMA
Coker, ML
Etoh, T
Spinale, FG
Citation: Jt. Peterson et al., Matrix metalloproteinase inhibition attenuates left ventricular remodelingand dysfunction in a rat model of progressive heart failure, CIRCULATION, 103(18), 2001, pp. 2303-2309
Authors:
Sliskovic, DR
Roth, BD
Citation: Dr. Sliskovic et Bd. Roth, Endocrine and metabolic agents - Preface, CUR PHARM D, 6(1), 2000, pp. NIL_2-NIL_3
Authors:
O'Brien, PM
Ortwine, DF
Pavlovsky, AG
Picard, JA
Sliskovic, DR
Roth, BD
Dyer, RD
Johnson, LL
Man, C
Hallak, H
Citation: Pm. O'Brien et al., Structure-activity relationships and pharmacokinetic analysis for a seriesof potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors, J MED CHEM, 43(2), 2000, pp. 156-166
Authors:
Roth, BD
Sliskovic, DR
Citation: Bd. Roth et Dr. Sliskovic, Endocrine and metabolic agents - Preface, CUR PHARM D, 5(9), 1999, pp. NIL_2-NIL_2
Authors:
Sliskovic, DR
Citation: Dr. Sliskovic, Endocrine and metabolic agents - Preface, CUR PHARM D, 5(1), 1999, pp. NIL_2-NIL_2
Authors:
Sliskovic, DR
Krause, BR
Bocan, TMA
Citation: Dr. Sliskovic et al., Atherosclerosis: Emerging pharmacological approaches, ANNU REP M, 34, 1999, pp. 101-110
Risultati:
1-9
|